Neogen Co. (NASDAQ:NEOG) Forecasted to Earn Q1 2026 Earnings of $0.12 Per Share

Neogen Co. (NASDAQ:NEOG - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Neogen in a note issued to investors on Tuesday, September 10th. William Blair analyst B. Vazquez forecasts that the company will post earnings per share of $0.12 for the quarter. The consensus estimate for Neogen's current full-year earnings is $0.54 per share. William Blair also issued estimates for Neogen's Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $0.20 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). Neogen had a negative net margin of 1.02% and a positive return on equity of 3.09%. The company had revenue of $236.80 million for the quarter, compared to analysts' expectations of $225.83 million. During the same quarter last year, the business posted $0.14 EPS. The business's quarterly revenue was down 2.1% compared to the same quarter last year.

A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler upped their price objective on shares of Neogen from $17.00 to $17.50 and gave the company a "neutral" rating in a research note on Tuesday, August 6th. StockNews.com raised shares of Neogen to a "sell" rating in a research note on Wednesday, September 4th.

Neogen Price Performance

NEOG stock traded up $0.25 during mid-day trading on Thursday, hitting $15.50. 980,057 shares of the stock were exchanged, compared to its average volume of 2,010,501. The business has a fifty day moving average price of $16.45 and a 200 day moving average price of $15.21. Neogen has a 12 month low of $11.46 and a 12 month high of $21.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.82 and a quick ratio of 2.59. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of 1,550.00 and a beta of 1.21.

Insiders Place Their Bets

In other Neogen news, Director James P. Tobin purchased 3,000 shares of the stock in a transaction on Tuesday, August 6th. The stock was acquired at an average price of $16.86 per share, with a total value of $50,580.00. Following the transaction, the director now directly owns 23,392 shares of the company's stock, valued at approximately $394,389.12. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.71% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Covestor Ltd raised its position in shares of Neogen by 173.2% in the 1st quarter. Covestor Ltd now owns 1,970 shares of the company's stock worth $31,000 after acquiring an additional 1,249 shares in the last quarter. Innealta Capital LLC bought a new position in Neogen in the second quarter worth $46,000. Headlands Technologies LLC lifted its position in Neogen by 264.1% during the second quarter. Headlands Technologies LLC now owns 3,397 shares of the company's stock valued at $53,000 after buying an additional 2,464 shares during the period. Family Firm Inc. bought a new stake in shares of Neogen during the 2nd quarter valued at $90,000. Finally, Quantum Private Wealth LLC purchased a new stake in shares of Neogen in the 2nd quarter worth about $156,000. 96.73% of the stock is owned by hedge funds and other institutional investors.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.